Iris Dorbian

LHP Hospital Group, which is backed by CCMP Capital Advisors, said Monday that it has named Mark Miller as executive vice president and CFO, effective July 29, 2013. In his new role, Miller will lead LHP’s corporate finance unit. Miller replaces William J. Hibbitt, who is retiring. Headquartered in Plano, Texas, LHP Hospital Group is a provider of resources to not-for-profit hospitals and health systems.

Private Equity Headhunters said Friday that it has named Jaree Zafar as its new chief technology officer. In his new position, Zafar will be responsible for managing the company's IT department. Based in Dallas, Private Equity Headhunters is an executive recruitment firm that specializes in the private equity/venture capital sector.

Greenwich, CT-based private investment firm Littlejohn & Co. said Friday that it is leading the acquisition and recapitalization of Handy Hardware. No financial terms were disclosed. The transaction, which is expected to close during the week of August 5, 2013, was approved on Thursday by the United States Bankruptcy Court for the District of Delaware as part of a Chapter 11 plan for Handy Hardware. Also, Doug Miller has been named interim CEO of Handy Hardware. Located in Houston, Handy Hardware is a wholesale hardware distributor to independent hardware retailers.

Silicon Valley-based VC firm Greylock Partners has promoted Josh Elman to partner, according to a blog post on the company's website. Most recently, Elman was the product lead for growth and relevance at Twitter. Prior to that, he worked on the platform at Facebook and led the launch of Facebook Connect. To find out more about Elman's promotion, read the post here.

Aqua Pharmaceuticals, a portfolio company of RoundTable Healthcare Partners, said Thursday that it has named Brett Fair as vice president of corporate development. In this role, Fair will be responsible for new products and development opportunities. Based in West Chester, Penn., Aqua Pharmaceuticals is a specialty pharmaceuticals company focused on dermatology products.

England & Company said Thursday that it has named Corey Luskin as a managing director in its technology investment banking group. Luskin, who will be based in the company's New York City office, previously worked at Dresdner Kleinwort Wasserstein, Smith Barney, Landmark Ventures and the Garros Group, where he was a member of the founding team. A middle-market merchant bank, England & Company has offices in both Washington, D.C. and New York City.

San Francisco-based MarketTools said Thursday that it has acquired RawData. No financial terms were disclosed. Headquartered in Salt Lake City, UT, RawData is a provider of mobile research solutions. MarketTools is a subsidiary of MetrixLab, a provider of online consumer research services. MetrixLab is backed by AlpInvest Partners and ZekVentures.

Onconova Therapeutics has raised about $77.5 million for its IPO. The company has priced its offering of 5,166,667 shares at $15.00 per share. The stock will begin trading on the NASDAQ on July 25, 2013 under the ticker symbol ONTX. Citigroup and Leerink Swann are the lead underwriters for the IPO while Piper Jaffray and Janney Montgomery Scott are co-managers. Based in Newton, Penn. and backed by Baxter International, ICICI Ventures, Mehta Partners and Tinicum Partners, Onconova is a biopharmaceutical company focused on developing drugs to treat cancer.

Lightyear Capital, a New York-based private equity firm focused on financial services investing, has named Richard Korhammer as senior advisor. Korhammer is co-founder and former chairman/CEO of Lava Trading.

Conatus Pharmaceuticals said Thursday that it has raised about $66 million for its IPO. The company has priced its offering of 6,000,000 shares at $11 per share. The stock will trade on the NASDAQ under the ticker symbol CNAT, starting on July 25, 2013. Stifel and Piper Jaffray & Co. are the lead underwriters for the IPO while JMP Securities and SunTrust Robinson Humphrey are the co-lead manager and co-manager respectively. Based in San Diego, Calif., Conatus Pharmaceuticals, which is backed by Aberdare Ventures, Advent Venture Capital, MPM Capital, AgeChem Venture Fund and Roche Finance, among others, is a biotech company focused on the treatment of liver disease.